BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $39 from $43 and keeps a Buy rating on the shares after the company reported a single grade 4 liver transaminase elevation in the phase 3 MAGNITUDE study for nex-z in transthyretin amyloid cardiomyopathy. Despite the relatively clean profile before today, the firm expects a safety overhang for the program until further data is available, the analyst tells investors. The firm still sees potential for a one-time treatment option in hereditary angioedema and ATTR markets, but lowers its view of the probability of success in ATTR-CM to 30% from 35% pending additional safety follow-ups for nex-z.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia adverse event could resurface questions, says JPMorgan
- Intellia discloses grade 4 liver transaminase elevation in MAGNITUDE trial
- Positive Outlook for Intellia Therapeutics Despite Safety Concerns in MAGNITUDE Trial
- Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study
- Closing Bell Movers: Nvidia gains 4% on earnings, lifting other semis
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue